Pandemic response

#Artificial intelligence (AI) #Immunology / Virology & Vaccines #NEC Bio #Pandemic response

EU project strengthens pandemic preparedness with AI vaccine design

PREPAIR VAC is a Horizon Europe-funded research project aimed at strengthening pandemic preparedness through the application of artificial intelligence (AI) in vaccine design.  NEC Corporation’s NEC OncoImmunity (NOI) will be working alongside several European partners comprising a research consortium.  The four-year research grant beginning in… Read More

#News

mRNA
#CEPI #Immunology / Virology & Vaccines #Influenza #Moderna #mRNA #Pandemic prevention #Pandemic response

$54.3m CEPI investment boosts Moderna’s H5 influenza vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI) is to invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure.   The organisation says the funding marks a significant step forward in global… Read More

#Business & Investment #News

Preparing Covid-19 vaccine for injection
#Immunology / Virology & Vaccines #Pandemic response #University of Queensland #Vaccine candidate #virus

Queensland researchers attempt 150-day vaccine challenge

Queensland researchers are attempting to create a vaccine in just 150 days to prove how far their response capabilities to a viral pandemic have come since Covid-19.  The clock started on 10 February 2025 for The University of Queensland’s Vaccine Rapid Response Team, which has been tasked… Read More

#News #Trending News

#Antibodies #Monoclonal antibodies #Pandemic prevention #Pandemic response

Polyclonal and recombinant antibody development

Joerg Schuettrumpf, Chief Scientific Innovation Officer at Grifols, discusses advancements in antibody therapies, focusing on IgA, IgM, and recombinant polyclonal technologies to enhance treatment efficacy, scalability, and preparedness for global health challenges. IgA and IgM therapies The therapeutic antibody field is progressing rapidly, says Schuettrumpf, with key advances in broad-spectrum… Read More

#Exclusive Content

#Immunology / Virology & Vaccines #Infectious diseases #Pandemic prevention #Pandemic response

Preparing for the next infectious disease pandemic

Dr Owain Millington, Chief Executive Officer at ILC Therapeutics, explores some of the areas of unmet need in infectious disease, and where the search for pleiotropic, broad-spectrum antivirals could lead drug development. Introduction Whilst the Covid-19 pandemic caused a step change in global investment for infectious diseases, there remains significant… Read More

#Exclusive Content

#Biological threats #Covid-19 #European Commission #Fabentech #Funding #Pandemic response

€20 million EIB financing to combat biological threats

The European Investment Bank (EIB) and the French biopharmaceutical company Fabentech have signed a €20 million loan to accelerate the development of broad-spectrum therapeutics to combat biological threats to public health. The deal is supported by the Health Emergency Preparedness and Response Authority (HERA), set up… Read More

#News

Antibodies attack Covid-19
#Covid-19 #Harvard Medical School #Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response #University of Oxford

AI tool predicts new viral variants and could improve vaccines

The UK’s University of Oxford is taking the lead on two collaborative international projects to improve the response to new Covid-19 variants and contribute to future pandemic preparedness. Researchers at Harvard Medical School (HMS) in the US and the University of Oxford have developed a new… Read More

#News #Trending News

Vaccine research
#Covid-19 #Disease X #Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response #UK

UK vaccine centre offers opportunity for pandemic preparedness

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘Disease X‘, a term used because what might trigger the next pandemic is unknown. Read More

#News #Trending News

#Covid-19 #Disease X #Pandemic prevention #Pandemic response

New podcast on Disease X: The 100 Days Mission to End Pandemics

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with Kate Kelland, author of Disease… Read More

#News

Dr Noushin Jaberolansar and Dr Andrew Young at lab bench
#Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response

Clamp2 provides vaccine hope for future pandemics

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial.  The Coalition for Epidemic Preparedness Innovation (CEPI) has committed up to AU$8.5 ($5.7) million to support further development of the re-engineered technology for use in the global response to… Read More

#News

Outbreak map of the world
#Covid-19 #Global.health #Infectious diseases #Monkeypox #Outbreak #Pandemic #Pandemic prevention #Pandemic response

Pandemic data platform will model emerging infectious diseases

The Rockefeller Foundation will provide $3 million in new funding for Global.health (G.h) – an open-source platform for scientific pandemic data.  The investment will allow the platform to expand its international partnerships and modernise the global effort around coordinated pandemic prevention, surveillance, and response. Co-developed by researchers and engineers… Read More

#Covid-19 #News